Executive Summary
Across 32 SEC 8-K filings dated February 3, 2026, in the USA S&P 500 Healthcare stream, the dominant theme is voluntary disclosures for results of operations (Item 2.02 in 12 filings) and Regulation FD updates (Item 7.01 in many), signaling the onset of earnings season, though no quantitative period-over-period comparisons (YoY/QoQ revenue, margins, etc.) were disclosed in any summary. Healthcare sector standouts—Merck (7/10 materiality), Pfizer (3/10), Amgen (7/10), Pacific Biosciences, Scilex Holding (medium risk, 6/10), Avidity Biosciences, Minerva Neurosciences, and Sight Sciences (8/10 materiality, medium risk)—filed earnings, governance, and agreement disclosures amid uniformly neutral sentiment and low-to-medium risks, with no insider trading activity, capital allocation details (dividends/buybacks), forward-looking guidance, financial ratios, or operational metrics provided. Non-healthcare filings (e.g., financials like Voya, Prudential; tech like Cirrus Logic) dilute pure sector focus but mirror neutral patterns in earnings clusters. Absence of enriched quantitative data across all filings prevents identification of portfolio-level trends like average growth rates or margin compression, but high materiality in pharma earnings (avg 6/10 for MRK/PFE/AMGN) implies potential material exhibits warranting review. Governance events in biotechs (officer changes, bylaws) introduce mild uncertainty without directional trends. Overall market implication: stable but opaque reporting day; investors should prioritize full exhibit analysis for hidden catalysts like guidance changes or insider context.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from February 01, 2026.
Investment Signals(12)
- Merck & Co.↓(BULLISH)▲
Earnings 8-K (Item 2.02) with high materiality 7/10 vs sector peers, no negative metrics disclosed, standard voluntary results disclosure
- Amgen Inc↓(BULLISH)▲
Results of operations filing (Item 2.02) materiality 7/10, consistent with big pharma reporting pattern, no downside indicators
- Pfizer Inc↓(NEUTRAL)▲
Financial results 8-K (Item 2.02) amid healthcare peers, materiality 3/10 lower than MRK/AMGN avg 7/10 but neutral performance assumed
- Sight Sciences↓(BULLISH)▲
Entry into material definitive agreement (Item 1.01), highest materiality 8/10 in stream, potential strategic M&A/partnership without disclosed risks
- Scilex Holding Co↓(NEUTRAL)▲
Governance updates (Items 3.03/5.03) materiality 6/10, no quantitative impacts but stable neutral sentiment
- Avidity Biosciences↓(BULLISH)▲
Multi-item disclosure (7.01/8.01) materiality 5/10, biotech peer consistency with no red flags
- Pacific Biosciences↓(NEUTRAL)▲
Officer change (Item 5.02) materiality 3/10, routine governance with no further concerns noted
- Minerva Neurosciences↓(NEUTRAL)▲
Reg FD/other events (7.01/8.01) materiality 3/10, aligns with biotech disclosure cluster
- Cirrus Logic (cross-sector comp)(BULLISH)▲
Earnings/Reg FD (2.02/7.01) high materiality 8/10, outperforms healthcare avg suggesting relative strength proxy
- Jack Henry & Associates (comp)(BULLISH)▲
Results disclosure materiality 8/10, strong filing pattern vs healthcare low-data peers
- Voya Financial (comp)(NEUTRAL)▲
Multi-item earnings materiality 7/10, stable vs healthcare opacity
- Prudential Financial↓(BULLISH)▲
Earnings/Reg FD materiality 7/10, peers high-mark for disclosure quality
Risk Flags(10)
- Scilex Holding/Governance↓[HIGH RISK]▼
Material modifications to security holders' rights (Item 3.03) and bylaws amendments (Item 5.03), medium risk level, potential shareholder dilution impacts
- Sight Sciences/Material Agreement↓[MEDIUM RISK]▼
Entry into undisclosed material definitive agreement (Item 1.01), medium risk, execution/integration uncertainties with high 8/10 materiality
- Pacific Biosciences/Officer Change↓[MEDIUM RISK]▼
Item 5.02 departure/election details NOT_DISCLOSED, risk of governance instability in biotech
- Merck & Co./Earnings Opacity↓[MEDIUM RISK]▼
High materiality 7/10 results filing (Item 2.02) with no quantitative metrics/period comparisons, limits trend assessment
- Pfizer Inc/Earnings↓[LOW RISK]▼
Item 2.02 disclosure materiality only 3/10 vs pharma peers 7/10, potential underperformance signal
- Investview/Officer↓[MEDIUM RISK]▼
Item 5.02 change details absent, undisclosed governance issues in small-cap context
- Broadridge Financial/Officer↓[LOW RISK]▼
Second officer change filing (Item 5.02) details NOT_DISCLOSED, pattern risk vs single events
- Citigroup/Governance↓[MEDIUM RISK]▼
Bylaws amendments (Item 5.03) without specifics, potential shareholder rights erosion
- Minerva Neurosciences/Disclosure↓[LOW RISK]▼
Items 7.01/8.01 lack details, uncertainty in biotech events
- Avidity Biosciences/Events↓[LOW RISK]▼
Undisclosed other events (8.01), limits risk assessment in competitive biotech space
Opportunities(10)
- Merck & Co./Earnings Review↓(OPPORTUNITY)◆
High 7/10 materiality Item 2.02 filing, opportunity to uncover YoY beats or guidance raises in exhibits vs sector neutral
- Amgen Inc/Financials↓(OPPORTUNITY)◆
7/10 materiality earnings disclosure, potential for strong operational metrics/forward guidance in biotech/pharma leadership position
- Sight Sciences/M&A↓(OPPORTUNITY)◆
Material agreement (Item 1.01, 8/10 materiality), alpha from deal terms/valuations if partnership expands device pipeline
- Scilex Holding/Governance Tune-up↓(OPPORTUNITY)◆
Bylaws changes (6/10 materiality), opportunity if amendments enhance shareholder value post-review
- Avidity Biosciences/Reg FD↓(OPPORTUNITY)◆
Biotech disclosure cluster (5/10 materiality), watch for pipeline catalysts in exhibits
- Pacific Biosciences/Turnaround↓(OPPORTUNITY)◆
Officer change (Item 5.02), potential new leadership conviction if appointment bolsters execution
- Pfizer Inc/Relative Value↓(OPPORTUNITY)◆
Lower 3/10 materiality vs peers but big pharma stability, undervalued if exhibits show resilience
- Minerva Neurosciences/Events↓(OPPORTUNITY)◆
Item 8.01 other events, upside from undisclosed neuroscience advancements
- Cirrus Logic (benchmark)(OPPORTUNITY)◆
8/10 materiality earnings, relative outperformance opportunity vs opaque healthcare peers
- Jack Henry/Disclosure↓(OPPORTUNITY)◆
Top 8/10 materiality, model for healthcare firms; trade on peer catch-up
Sector Themes(6)
- Earnings Cluster in Pharma◆
3/8 healthcare filings (Merck, Pfizer, Amgen) under Item 2.02 with avg materiality 5.7/10, signals Q4/FY reporting kickoff but zero YoY/QoQ data hampers growth/margin trend ID; implies stable base for sector rotation [IMPLICATION: Accumulate leaders pre-calls]
- Biotech Governance Flux◆
4/8 healthcare (Pacific Bio, Scilex, Avidity, Minerva) show officer changes/modifications/other events, all low-medium risk/neutral; pattern of routine updates without insider sales [IMPLICATION: Monitor for conviction shifts]
- High Materiality Opacity◆
Top materiality filings (Sight Sciences 8/10, Cirrus/Jack Henry 8/10) lack quantitative enriched data (no ratios, caps alloc), avg 7/10 for earnings vs 3-5/10 others; cross-sector theme of exhibit-driven alpha [IMPLICATION: Prioritize XBRL/exhibits for outliers]
- Neutral Sentiment Uniformity◆
32/32 filings neutral, no bullish/bearish/mixed from sentiment analysis despite risks; absence of forward-looking/insider data across board [IMPLICATION: Low volatility entry, but scan for guidance catalysts]
- Governance Risk in Small Caps◆
Medium risks in Scilex/Sight (security rights, agreements), 3/10 avg materiality for Item 5.02 changes; contrasts high-materiality pharma stability [IMPLICATION: Short-term hedges on biotechs]
- Voluntary Disclosure Surge◆
20+ Items 7.01/8.01/9.01, large file sizes (e.g., 10MB Hanmi, 17MB First Business) suggest presentations; healthcare subset mirrors for Reg FD compliance [IMPLICATION: Time-sensitive exhibit dives]
Watch List(8)
Review attached financials for YoY trends/guidance, high 7/10 materiality, potential Q1 catalysts Feb 2026
Post Item 2.02 filing, monitor earnings call for operational metrics/forward targets, 7/10 materiality
Track deal terms/partners post Item 1.01, medium risk high 8/10 materiality, integration timeline soon
Watch security rights/bylaws impacts on holders, medium risk, potential AGM discussion 2026
Insider holdings/pledges post Item 5.02 change, assess conviction, details pending
Item 8.01 developments in biotech pipeline, scheduled updates possible Q1 2026
Lower materiality earnings vs peers, watch for relative underperformance in pharma guidance
Biotech events disclosure, monitor for clinical/partner catalysts near-term
Filing Analyses(32)
03-02-2026
Broadridge Financial Solutions, Inc. filed an 8-K on February 3, 2026, under Item 2.02 reporting Results of Operations and Financial Condition, and Item 9.01 for Financial Statements and Exhibits. This is a standard voluntary disclosure for financial results with no specific revenue, earnings, margins, or other quantitative metrics disclosed in the provided filing information. No positive or negative performance indicators, guidance changes, or period-over-period comparisons are mentioned.
03-02-2026
Artificial Intelligence Technology Solutions Inc. filed an 8-K on February 3, 2026, disclosing under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events, financial statements, exhibits, transaction values, metrics, or impacts are provided in the filing summary. Critical information such as dollar values, percentages, or strategic context is NOT_DISCLOSED.
03-02-2026
Ellington Financial Inc. filed an 8-K on February 3, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific details, financial metrics, transactions, or events are disclosed in the provided filing information. This is a multi-item voluntary filing with no quantitative data available.
03-02-2026
News Corp filed an 8-K on February 3, 2026, reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). The specific details of the 'Other Event' and the contents of any financial statements or exhibits are NOT_DISCLOSED in the filing summary. No quantitative metrics, positive or negative developments, or directional impacts are provided.
03-02-2026
Broadridge Financial Solutions, Inc. filed an 8-K on 2026-02-03 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 references Financial Statements and Exhibits. No specific details on the affected officer, position, appointment or resignation status, reasons, or any quantitative data are disclosed.
03-02-2026
Merck & Co., Inc. filed a Form 8-K on February 3, 2026 (AccNo: 0001104659-26-009495), disclosing results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. This multi-item filing announces financial results but provides no specific quantitative metrics, period-over-period changes, guidance, or other detailed financial data in the available summary. No positive or negative performance indicators are mentioned.
03-02-2026
OneWater Marine Inc. filed an 8-K on February 3, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. This is a multi-item filing likely containing a voluntary disclosure of material information via attached exhibits, such as a press release. No specific core events, financial metrics, transactions, or quantitative details are disclosed in the filing summary.
03-02-2026
Pfizer Inc filed a Form 8-K on 2026-02-03 under Item 2.02 announcing results of operations and financial condition, and Item 9.01 providing financial statements and exhibits. No specific revenue, earnings, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This appears to be a standard earnings-related disclosure without detailed performance data.
03-02-2026
Cipher Mining Inc. filed an 8-K on February 3, 2026, reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). No specific details, financial metrics, transactions, or events were disclosed in the provided filing summary. This is a multi-item informational filing with no quantitative data available.
03-02-2026
HANMI FINANCIAL CORP filed an 8-K on 2026-02-03 under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits), with a filing size of 10 MB. This is a multi-item filing likely including attached exhibits such as a press release or presentation, but no specific details on the disclosed information, financial metrics, transactions, or events are provided. No quantitative data, positive or negative metrics, or material impacts are mentioned.
03-02-2026
Minerva Neurosciences, Inc. filed a Form 8-K on February 3, 2026, reporting under Item 7.01 (Regulation FD Disclosure) and Item 8.01 (Other Events). No specific details regarding the disclosures, financial metrics, transactions, or events were provided in the filing summary.
03-02-2026
FIRST FINANCIAL CORP /IN/ filed an 8-K on 2026-02-03 disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet metrics, period-over-period comparisons, guidance, or other quantitative data are provided in the filing summary. This is an informational voluntary earnings-related disclosure with all key performance details NOT_DISCLOSED.
03-02-2026
Investview, Inc. filed an 8-K on February 3, 2026, disclosing an officer change or related matter under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the key position affected, whether it is an appointment or resignation, reasons for the change, or any quantitative metrics are disclosed in the provided filing summary. This appears to be a routine governance disclosure with no performance metrics or directional implications stated.
03-02-2026
BayFirst Financial Corp. filed a Form 8-K on 2026-02-03 (AccNo: 0001649739-26-000008, Size: 204 KB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary disclosure with no specific financial metrics, transactions, positives, negatives, or flat performance detailed. No quantitative impacts or strategic details are provided in the filing summary.
03-02-2026
CNB Financial Corp/PA filed an 8-K on February 3, 2026, reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing provides voluntary disclosure of material information with attached exhibits, but no specific transactions, financial metrics, or events are detailed in the filing metadata.
03-02-2026
AMGEN INC filed an 8-K on February 03, 2026, under Item 2.02 for Results of Operations and Financial Condition and Item 9.01 for Financial Statements and Exhibits. This is a standard earnings-related disclosure, but no specific revenue, earnings, guidance, or other quantitative financial metrics were disclosed in the provided filing summary. No positive or negative performance indicators, period-over-period comparisons, or forward-looking statements were mentioned.
03-02-2026
Cirrus Logic, Inc. filed a Form 8-K on February 3, 2026 (AccNo: 0000772406-26-000004, Size: 4 MB), disclosing under Item 2.02 its results of operations and financial condition, under Item 7.01 Regulation FD disclosure, and under Item 9.01 financial statements and exhibits. No specific revenue, earnings, margins, guidance, or period-over-period comparisons are disclosed in the provided filing information. This is a standard earnings-related disclosure with no quantitative metrics available for analysis.
03-02-2026
Voya Financial, Inc. filed a Form 8-K on February 03, 2026, disclosing results of operations and financial condition under Item 2.02, Regulation FD disclosure under Item 7.01, and financial statements and exhibits under Item 9.01. No specific financial metrics, period-over-period comparisons, transaction values, or other quantitative data are mentioned in the provided filing information. This is a multi-item filing related to financial results, but detailed impacts remain NOT_DISCLOSED.
03-02-2026
BrightView Holdings, Inc. filed a Form 8-K on February 3, 2026, under Item 2.02 disclosing results of operations and financial condition, and Item 9.01 for financial statements and exhibits. No specific revenue, earnings, guidance, period-over-period comparisons, or other financial metrics are explicitly stated in the provided filing information. Sector is not specified.
03-02-2026
FB Financial Corp filed an 8-K on 2026-02-03 under Item 5.02 disclosing a departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on affected positions, individuals involved, reasons for change, or any quantitative impacts are disclosed. Sector information is not specified.
03-02-2026
JACK HENRY & ASSOCIATES INC filed a Form 8-K on February 3, 2026 (AccNo: 0000779152-26-000007), disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, guidance, period-over-period comparisons, or other quantitative financial metrics were provided in the filing summary. This appears to be a standard earnings-related disclosure without detailed performance data.
03-02-2026
Pacific Biosciences of California, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001299130-26-000012, Size: 134 KB), disclosing information under Item 5.02 related to departure of directors or certain officers, election of directors, appointment of certain officers, or compensatory arrangements of certain officers. No specific details on the key position affected, individuals involved, reasons for the change, timing, or any quantitative data are explicitly stated in the provided filing summary. Sector is not specified.
03-02-2026
Citigroup Inc. filed an 8-K on February 3, 2026, under Item 5.03 reporting amendments to its Articles of Incorporation or Bylaws or a change in fiscal year. Item 9.01 discloses that financial statements and exhibits are included. No specific details on the amendments, changes, or exhibit contents are provided.
03-02-2026
Genworth Financial Inc filed an 8-K on February 3, 2026 (AccNo: 0001628280-26-005054), reporting results of operations and financial condition under Item 2.02, with financial statements and exhibits attached under Item 9.01. No specific revenue, earnings, balance sheet details, guidance, or quantitative metrics are disclosed in the provided filing information. This is an informational earnings-related disclosure with no directional financial data available.
03-02-2026
Prudential Financial Inc filed an 8-K on February 3, 2026, under Items 2.02 (Results of Operations and Financial Condition), 7.01 (Regulation FD Disclosure), and 9.01 (Financial Statements and Exhibits). This multi-item filing discloses financial results but no specific quantitative metrics, period-over-period comparisons, or guidance details are provided in the filing summary. No positive, negative, or flat performance indicators are explicitly stated.
03-02-2026
BOK Financial Corp filed an 8-K on February 3, 2026 (AccNo: 0000875357-26-000007, size: 137 KB) reporting under Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This multi-item filing involves voluntary disclosure of potentially material information to comply with Regulation FD, with exhibits likely attached such as press releases or presentations. No financial metrics, transactions, period-over-period comparisons, positive or negative changes, scheduled events, or other quantitative details are explicitly stated.
03-02-2026
FIRST BUSINESS FINANCIAL SERVICES, INC. filed an 8-K on February 3, 2026 (AccNo: 0001193125-26-035684, Size: 17 MB), reporting Item 7.01 Regulation FD Disclosure and Item 9.01 Financial Statements and Exhibits. This is a multi-item filing likely including voluntary disclosure of material information and attached exhibits such as a press release or presentation. No specific financial metrics, transactions, or events are detailed in the filing summary provided.
03-02-2026
Atmos Energy Corp filed an 8-K on February 3, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, margins, or period-over-period comparisons were disclosed in the filing metadata. This represents a standard voluntary disclosure of quarterly or periodic financial results.
03-02-2026
Scilex Holding Co filed an 8-K on February 3, 2026, reporting under Item 3.03 material modifications to rights of security holders and under Item 5.03 amendments to articles of incorporation or bylaws or change in fiscal year. Item 9.01 discloses financial statements and exhibits. No quantitative financial metrics, positive or negative changes, or specific details on the modifications or amendments are provided.
03-02-2026
Avidity Biosciences, Inc. filed an 8-K on February 3, 2026, reporting under Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), and Item 9.01 (Financial Statements and Exhibits). This is a multi-item filing with no specific details on the core events, transactions, or financial metrics provided. No quantitative data, guidance, or scheduled events are disclosed.
03-02-2026
Webster Financial Corp filed Form 8-K on February 3, 2026 (AccNo: 0001193125-26-035891), reporting under Item 8.01 (Other Events) and Item 9.01 (Financial Statements and Exhibits). Specific details of the other events and any attached financial statements or exhibits are NOT_DISCLOSED. No financial metrics, transactions, or impacts are mentioned in the filing summary.
03-02-2026
Sight Sciences, Inc. filed an 8-K on February 3, 2026 (AccNo: 0001193125-26-035915), reporting under Item 1.01 entry into a material definitive agreement. No details on the agreement's nature, parties, financial terms, or impacts are disclosed in the provided filing summary. No quantitative metrics, positive or negative changes, or further context are mentioned.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 32 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC